Proceed with caution: Peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials

Hepatology

Volumn 52, Issue 6, 2010, Pages 2240-2241

  Kershenobich, David ^a   Muñoz, Linda ^b   Malé, René ^c   Gaytan, Jesús ^d   Sánchez, Francisco ^e  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c Hepatic Health Guadalajara   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e Nutrición Salvador Zubirán   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LETTER; NEUTROPENIA; PEER REVIEW; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOM SAMPLE; STRATIFIED SAMPLE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; META-ANALYSIS AS TOPIC; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78649597268     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24025     Document Type: Letter

References (12)

1. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. HEPATOLOGY 2010; 51: 1176-1184.
2. Leandro G. Meta-Analysis in Medical Research: The Handbook for the Understanding and Practice of Meta-Analysis. Oxford, UK: Blackwell Publishing Ltd.; 2005.
3. Kulinskaya E, Morgenthaler S, Staudte RG. Meta Analysis: A Guide to Calibrating and Combining Statistical Evidence. Chichester, UK: John Wiley & Sons Ltd.; 2008.
4. Sinha S, Gulur P, Patel V, Hage-Nassar G, Tenner S. A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C [Abstract]. Am J Gastroenterol 2004; 99: 237.
5. Kolakowska A, Berok H, Wasilewski M, Horbon A. Relevance between fibrosis and response to treatment with peginterferon alf2 vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study [Abstract]. HEPATOLOGY 2008; 48: 1278.
6. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-122.
7. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-115.
8. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
9. Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. HEPATOLOGY 2009; 49: 22-31.
10. Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, et al. Peg-interferon alpha-2a versus peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008; 28: 623-630.
11. Yenice N, Mehtap O, Gumrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006; 17: 94-98.
12. Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Monthly 2010; 10: 121-131.